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OBJECTIVE—A major determinant of the progression from
insulin resistance to the development of overt type 2 diabetes is
a failure to mount an appropriate compensatory -cell hyperplas-
tic response to maintain normoglycemia. We undertook the
present study to directly explore the signiﬁcance of the cell cycle
protein cyclin D2 in the expansion of -cell mass in two different
models of insulin resistance.
RESEARCH DESIGN AND METHODS—We created com-
pound knockouts by crossing mice deﬁcient in cyclin D2 (D2KO)
with either the insulin receptor substrate 1 knockout (IRS1KO)
mice or the insulin receptor liver-speciﬁc knockout mice
(LIRKO), neither of which develops overt diabetes on its own
because of robust compensatory -cell hyperplasia. We pheno-
typed the double knockouts and used RT-qPCR and immunohis-
tochemistry to examine -cell mass.
RESULTS—Both compound knockouts, D2KO/LIRKO and
D2KO/IRS1KO, exhibited insulin resistance and hyperinsulin-
emia and an absence of compensatory -cell hyperplasia. How-
ever, the diabetic D2KO/LIRKO group rapidly succumbed early
compared with a relatively normal lifespan in the glucose-
intolerant D2KO/IRS1KO mice.
CONCLUSIONS—This study provides direct genetic evidence
that cyclin D2 is essential for the expansion of -cell mass in
response to a spectrum of insulin resistance and points to the
cell-cycle protein as a potential therapeutic target that can be
harnessed for preventing and curing type 2 diabetes. Diabetes
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T
he maintenance of an adequate and functional
pancreatic -cell mass dictates the body’s ability
to compensate for insulin resistance. Recent
studies in autopsy samples from humans re-
ported expansion of -cell mass from infants through
adolescence that was largely due to increased islet size
(1). Further, humans with established type 2 diabetes
exhibit a deﬁcit in -cell mass in comparison with their
nondiabetic cohorts (2,3). Interestingly, obese, nondia-
betic patients express a wide range of -cell mass that is
sufﬁcient to maintain euglycemia up to a speciﬁc thresh-
old, and crossing the threshold correlates with impaired
fasting glucose and clinical diabetes (4).
While direct data in humans is lacking, studies in rodents
clearly indicate that -cell mass adaptively expands to com-
pensate for both physiological and pathophysiological states
of insulin resistance including pregnancy, onset of obesity,
and high-fat feeding and after partial pancreatectomy
(5–9). Although the adaptation is dependent on alterations
in both the number and size of -cells and generation of
new -cells from endogenous progenitors (10,11), recent
studies point to replication as a primary mechanism for
the physiological maintenance of adult -cell mass (12)
and in response to insulin resistance in both rodents and
humans (9,12–15).
Replication is achieved by reentry of the -cell into the
cell cycle and relies on proteins regulating the G1 phase
(13,16–19). Our previous work has established that cyclin
D2, a G1/S cell-cycle regulator, is necessary for the post-
natal expansion of -cell mass (13). In these studies, we
observed that in the absence of cyclin D2, the diminished
-cell mass established during the neonatal remodeling
period was inadequate to sufﬁciently respond to metabolic
demand for insulin in adult mice, leading to glucose
intolerance but not frank diabetes (13). While these exper-
iments indicate that cyclin D2 is important during early
postnatal expansion of -cells for the adult mouse to
achieve its optimal -cell mass, its importance in cell
expansion in response to a pathophysiological demand for
insulin is not known. Considering these observations, we
explored whether a limited but adequate -cell mass that
is challenged by physiological stress would fall below a
functional threshold required to maintain euglycemia, and
eventually to promote the development of diabetes, using
cyclin D2 knockout mice. To this end, we created com-
pound double knockouts by breeding cyclin D2 (D2KO)
mice with either mice that are deﬁcient in insulin receptor
substrate 1 (IRS1KO) (20,21) or mice with a knockout of
the insulin receptor speciﬁcally in liver (LIRKO) (22).
These models reﬂect the spectrum of insulin resistance
and glucose intolerance observed in humans but do not
develop frank diabetes in part because of compensatory
-cell expansion that can increase from 3-fold (IRS1KO) to
30-fold (LIRKO) largely by replication of -cells (21,23).
Our results indicate that both D2KO/LIRKO and D2KO/
IRS1KO double-knockout mice fail to show a -cell com-
pensatory response to insulin resistance, leading to overt
diabetes that is secondary, in part, to a dramatic decrease
in -cell mass due to reduced -cell replication. These data
provide genetic evidence that cyclin D2 is essential for the
compensatory increase in -cell hyperplasia in response to
insulin-resistant states.
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Animal breeding and genotyping. All studies and procedures were per-
formed after approval according to the institutional animal committee regu-
lations in both institutions. The creation and characterization of the LIRKO,
IRS1KO, and D2KO mice has previously been described (20–22,24). All mice
were maintained on a 12-h light/12-h dark cycle with ad libitum access to
water and food, and a mixed mating scheme was adopted for breeding. In the
ﬁrst group, males and females homozygous for loxP sites (IRLox) and
expressing Cre recombinase on an albumin promoter were bred with mice
lacking cyclin D2. In the second group, males and females carrying either the
insulin receptor substrate 1 or cyclin D2 alleles were used. In the D2KO/LIRKO
study, the breeding generated mice homozygous for loxP (controls), LIRKO,
D2KO/LIRKO, and D2KO, and in the D2KO/IRS1KO study the genotypes
included IRS1KO (cycD2
/;irs1
/), D2KO/IRS1KO (cycD2
/;irs1
/),
D2KO (cycD2
/;irs1
/), and their controls (cycD2
/;irs1
/). DNA ex-
tracted from tails was used for PCR-based genotyping (13,22). All studies
included animals from a mixed genetic background. Pancreata were collected
for immunohistochemical analyses (25), and islets were isolated using previ-
ously described methods (26).
Glucose and insulin tolerance tests and plasma insulin levels. Following
a 16-h fast, baseline blood glucose levels were measured from tail-vein
samples using a glucometer (LifeScan, Milpitas, CA). Glucose tolerance
tests were performed (25) in 7-week-old (D2KO/LIRKO) or 25-week-old
(D2KO/IRS1KO) mice. Plasma insulin levels were measured by ELISA
(Linco Research). Insulin tolerance tests were performed on 25-week-old
mice (25).
Real-time RT–quantitative PCR. Quantitative real-time RT-PCR was per-
formed on total RNA samples extracted from islets (RNeasy Mini Kit; Qiagen,
Valencia, CA). cDNA samples were ampliﬁed by using the SYBR Green PCR
Master Mix (Applied Biosystems) and analyzed on an ABI PRISM 7900
sequence detection system (Applied Biosystems). All primer sequences are
available in the online appendix, available at http://diabetes.diabetesjournals.
org/cgi/content/full/db09-0838/DC1.
Immunohistochemistry and -cell mass analyses. The pancreata were
processed for immunohistochemical analyses as previously described (25).
Primary antibodies included the following: mouse anti-glucagon (1:1,000;
Sigma), guinea pig anti-insulin (1:500; Dako), rabbit anti-somatostatin (1:50;
Abcam), rabbit anti–Ki-67 (1:50; BD Biosciences), cyclin D1 (1:800; Santa Cruz
Biotechnology), rabbit anti–cyclin D2 (1:4,000; Santa Cruz Biotechnology),
cyclin D3 (1:200; Santa Cruz Biotechnology), goat anti–PDX-1 (1:300; gift from
C.V.E. Wright, PhD, Department of Cell and Developmental Biology, Vander-
bilt University, Nashville, TN), rabbit anti-FoxO1 (1:50; Cell Signaling Tech-
nology), and rabbit anti-GLUT2 (1:100; Alpha Diagnostic). DAPI (Sigma-
Aldrich) was used for nuclear staining. -Cell size was assessed by quantifying
the area of cells that costained with -catenin (mouse monoclonal antibody;
BD Biosciences) and insulin using ImageJ software (http://rsb.info.nih.gov/ij/).
-Cell mass was analyzed as previously described (27).
Statistical analyses. All data are expressed as means  SEM. Statistical
signiﬁcance was determined by an unpaired Student’s t test or ANOVA as
appropriate, and a P value 0.05 was used to reject the null hypothesis.
RESULTS
D2KO/LIRKO mice exhibit severe hyperglycemia and
early diabetes. We crossed the LIRKO mice with D2KO
mice to generate compound double knockouts to investigate
the requirement of cyclin D2 in the -cell compensatory
response to insulin resistance. Qualitatively similar data were
obtained in females and males. Therefore, only data from
males are reported. All mice were born in a normal Mende-
lian ratio, and we did not observe embryonic lethality.
However, we observed an early lethality in the double
knockouts, with several mice dying by age 3 months.
Therefore, we phenotyped 7-week-old animals and used 10-
to 12-week-old mice for islet isolation for gene expression or
dissected the pancreas for immunohistochemistry.
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FIG. 1. D2KO/LIRKO mice exhibit severe hyperglycemia and early
diabetes. A and B: Plasma insulin (A) and glucagon (B) levels were
measured at random fed states in control (white), LIRKO (light gray),
D2KO/LIRKO (black), and D2KO (dark gray) mice (n  4–10). *P <
0.05 as indicated by bars. C: Glucose tolerance tests were performed in
7-week-old mice, and blood glucose was measured at 0, 15, 30, 60, and
120 min after intraperitoneal (IP) injection of glucose (2 g/kg body
wt). *P < 0.05 vs. controls; n  4–8.
TABLE 1
Body weight and blood glucose of mice
Body
Weight
(g)
P vs.
control
Nonfasted
blood
glucose
(mg/dl)
P vs.
control
10–12 weeks of
age
Control 24.8  1.5 149  9
LIRKO 24.2  1.7 NS 198  40 NS
D2KO/LIRKO 18.5  1.4 0.01 600 0.000,001
D2KO 19.7  1.4 0.024 188  22 0.042
25 weeks of age
Control 23.1  0.9 172  5
IRS1KO 18.4  1.1 0.012 176  9N S
D2KO/IRS1KO 13.5  0.4 0.005 390  41 0.005
D2KO 21.2  0.8 NS 253  18 0.005
Data are means  SE (n  5–9 male mice). NS, nonsigniﬁcant.
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between LIRKO and control mice (Table 1), as reported
previously (22). Consistent with previous data (23), LIRKOs
exhibited hyperinsulinemia compared with controls (Fig.
1A), and no signiﬁcant differences were observed in blood
glucose between groups in 10- to 12-week-old mice. The
D2KOs were smaller than the controls and exhibited mild
hyperglycemia that was secondary to hypoinsulinemia (Ta-
ble 1; Fig. 1A). On the other hand, the compound double
knockouts showed a signiﬁcant decrease in body weight,
severe hyperglycemia (600 mg/dl) (Table 1), and hyperin-
sulinemia, although their absolute insulin levels were still
signiﬁcantly lower than those in individual LIRKO mice (Fig.
1A). Further, the circulating glucagon levels were signiﬁ-
cantly increased in the double knockouts compared with
those of all other groups (Fig. 1B).
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FIG. 2. Absence of cyclin D2 limits islet hyperplasia in LIRKO mice. A: Real-time RT-qPCR was performed on RNA extracted from islets of control,
LIRKO, D2KO/LIRKO, and D2KO mice (n  4–9). Results are normalized to TATA-binding protein (TBP) and expressed relative to controls. *P <
0.05 vs. groups as indicated. B: Triple immunostaining for insulin (blue), somatostatin (green), and glucagon (red) on pancreas sections from
control, LIRKO, D2KO/LIRKO, and D2KO mice. A representative islet for each group at magniﬁcation 40 is presented (n  4). C: Relative islet
size was assessed from triple immunostaining (presented in B). Quantiﬁcation with Image J software of islet area is presented (means  SEM
from n >10 islets counted per mouse; n  4–6 in each group). D: -Cell mass was assessed as described in RESEARCH DESIGN AND METHODS (n  4–6).
E: Relative -cell size was assessed by coimmunostaining for -catenin, insulin, and DAPI in pancreas sections from control, LIRKO,
D2KO/LIRKO, and D2KO mice (n  4–6). Quantiﬁcation with Image J software of relative -cell area is presented (means  SEM from n >100
cells counted per mouse; n  4–6 in each group). F: -Cell proliferation was assessed by coimmunostaining for Ki-67, insulin, and DAPI in
pancreas sections from control, LIRKO, D2KO/LIRKO, and D2KO mice. Respective replication index is presented. *P < 0.05 vs. groups as
indicated; n  4–6. In all cases, at least two to three pancreas sections were used for each animal. (A high-quality digital representation of this
ﬁgure is available in the online issue.)
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were glucose intolerant but were not severely diabetic
despite a diminished -cell mass (13). In this study, we
observed severe intolerance as early as 7 weeks of age in
both the LIRKO and D2KO/LIRKO mice compared with
both the controls and the mildly glucose-intolerant D2KOs
(Fig. 1C). These data indicate that absence of cyclin D2 in
LIRKO mice leads to overt diabetes and early death in the
double mutants.
Absence of cyclin D2 limits islet hyperplasia in
LIRKO mice. To evaluate the alterations in islet morphol-
ogy, we analyzed pancreas sections by immunohistochem-
istry using a cocktail of antibodies to non–-cell hormones
(Fig. 2B). In parallel, we measured hormone gene expres-
sion using quantitative real-time RT-qPCR, and these re-
sults are presented in Fig. 2A. The signiﬁcant increase in
insulin gene expression observed in LIRKO islets was lost
in the double knockout islets (Fig. 2A) and was consistent
with the relatively lower circulating insulin levels in the
double knockouts (Fig. 1A). On the contrary, the reduced
glucagon gene expression observed in LIRKO islets was
not detected in D2KO/LIRKO islets and in fact the circu-
lating glucagon levels were increased in the double knock-
outs (Fig. 1B). Further, the decrease in somatostatin gene
expression in the LIRKO group was attenuated in the
D2KO/LIRKO islets.
Examination of pancreas sections revealed a normal
islet architecture and cell distribution in all groups (Fig.
2B). As expected, we observed robust islet hyperplasia in
the LIRKO mice compared with islet hypoplasia in the
D2KO pancreas. Despite the hyperinsulinemia and insulin
resistance, the D2KO/LIRKO mice failed to show islet
hyperplasia and presented a morphology that was largely
similar to that observed in D2KO islets.
Whereas the size of islets is increased in the LIRKO
group compared with that in controls, it was reduced in
D2KO/LIRKO and D2KO mice (Fig. 2B and C). This ab-
sence of hyperplasia in D2KO/LIRKO islets was associated
with a dramatic decrease in -cell mass (Fig. 2D). Consis-
tent with our previous report (23), LIRKO islets showed a
2.4-fold increase in -cell mass compared with controls as
a result of hyperplasia (Fig. 2F) rather than hypertrophy
(Fig. 2E). Interestingly, quantiﬁcation of -cell size re-
vealed a slight but signiﬁcant increase in the double
mutants, suggesting an attempt to compensate for the
reduced -cell mass (Fig. 2E). Therefore, to assess
whether the absence of -cell hyperplasia in D2KO/LIRKO
pancreas was due to the inability of these cells to replicate
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FIG. 3. Increased expression of cyclin D2 in LIRKO islets. A: Real-time RT-qPCR was performed on RNA extracted from islets of LIRKO (light
gray) or control (white) mice (n  4). Results are normalized to TATA-binding protein (TBP) and expressed relative to controls. *P < 0.05 for
LIRKO vs. controls. B: Coimmunostaining of cyclin D2 (green) with insulin (red) and DAPI (blue) in pancreas sections from control and LIRKO
mice. One to two representative islets for each group at magniﬁcation 40x are presented (n  3). In all cases at least two to three pancreas
sections were used for each animal. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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Ki-67, a marker of replication, by immunohistochemistry
and measured the replication index by computing the ratio
of Ki-67
/insulin
 double-positive cells to the total num-
ber of insulin
 cells (Fig. 2F). A decrease in replicating
-cells in the double knockouts compared with LIRKO
islets suggested that the loss of hyperplasia in the D2KO/
LIRKO mice is, in part, secondary to reduced -cell
proliferation. These data indicate that absence of cyclin
D2 leads to a signiﬁcantly reduced -cell replication and a
poor islet hyperplastic response to insulin resistance.
Evaluation of cell death by transferase-mediated dUTP
nick-end labeling immunostaining did not reveal signiﬁ-
cant differences between groups (data not shown).
Further evidence for a role for cyclin D2 in -cell
proliferation (13,28) emerges from our studies in the
hyperplastic islets isolated from 4- to 6-month-old insulin-
resistant LIRKO mice (22). We observed a signiﬁcant
increase in transcripts for all three cyclins that was
consistent with enhanced -cell replication in the LIR-
KOs (Fig. 3A). Further, immunostaining conﬁrmed the
expression of cyclins at the protein level, with cyclin D2
showing a more intense nuclear staining than that in
controls (Fig. 3B).
Regulation of pancreatic duodenal homeobox-1 and
GLUT2 in D2KO/LIRKO islets. We subsequently fo-
cused on examining the expression of forkhead box 1
(FoxO1) and pancreatic duodenal homeobox-1 (PDX-1)—
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FIG. 4. Regulation of PDX-1 and GLUT2 expression in D2KO/LIRKO islets. A and C: Real time RT-qPCR was performed on RNA extracted from
control, LIRKO, D2KO/LIRKO, and D2KO islets. Results are normalized to TATA-binding protein (TBP) and expressed relative to controls. *P <
0.05 in comparison with controls as indicated; n  4. B: Coimmunostaining of PDX-1 (red) and FoxO1 (green) with DAPI (blue) in pancreas
sections from control, LIRKO, D2KO/LIRKO, and D2KO mice. A representative islet for each group at magniﬁcation 40 is presented (n  4). D:
Coimmunostaining of GLUT2 (green) and insulin (red) with DAPI (blue) in pancreas sections from control, LIRKO, D2KO/LIRKO, and D2KO
mice. A representative islet for each group at magniﬁcation 40 is presented (n  4). In all cases, at least two to three pancreas sections were
used for each animal. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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(rev. in 14,29–32). Consistent with a previous report that
PDX-1 is required for the compensatory -cell growth
response to insulin resistance (14), PDX-1 gene expression
(Pdx-1) was signiﬁcantly lower in the islets isolated from
D2KO/LIRKO or D2KO mice than in those in controls (Fig.
4A). Further, PDX-1 protein was either virtually undetect-
able by immunostaining or severely reduced in D2KO/LIRKO
-cells in most of the islets from these two groups (Fig. 4B).
On the other hand, islet gene expression for FoxO1 was not
signiﬁcantly different between groups (data not shown).
However, evaluation of FoxO1 protein levels by immuno-
staining showed little nuclear but largely cytoplasmic stain-
ing in -cells in the D2KO/LIRKO and D2KO islets compared
with LIRKO or control islets (Fig. 4B).
Considering that PDX-1 is known to regulate several
-cell–speciﬁc genes (33,34), we analyzed the expression
of GLUT2, a key marker of -cell function by real-time
RT-qPCR and immunostaining. GLUT2 gene expression
(SLC2A2) was decreased in islets from each knockout
group but more severely reduced in D2KO/LIRKO islets
(Fig. 4C), which correlated with the severe hyperglycemia
in these mice compared with single-knockout counterparts
(Table 1). At the protein level, GLUT2, like PDX-1, was either
virtually absent or severely reduced in D2KO/LIRKO -cells
(Fig. 4D), thereby implicating a role for the transporter in the
worsening of diabetes in the D2KO/LIRKO mice. These data
indicate that a deﬁciency of cyclin D2 in the context of
insulin resistance is associated with altered expression of
PDX-1 and its downstream targets, with potential implica-
tions for poor -cell proliferation and function.
D2KO/IRS1KO mice manifest hypoinsulinemia, glu-
cose intolerance, and hyperglycemia. In a parallel
study, we crossed D2KO mice with another model of
insulin resistance, the IRS1KOs, which exhibit mild insulin
resistance and a compensatory increase in -cell mass to
maintain euglycemia (20,21). For clarity, we will refer to
cycD2
/;irs1
/ animals as D2KO, cycD2
/;irs1
/ as
IRS1KO, cycD2
/;irs1
/ double heterozygotes as con-
trol, and cycD2
/;irs1
/ as double knockouts (D2KO/
IRS1KO). The IRS1KO animals exhibited reduced body
mass at weaning and were easily identiﬁable (20). The
D2KO/IRS1KO animals were generally smaller than
IRS1KO or D2KO animals (Table 1). By age 25 weeks,
D2KO/IRS1KO animals remained smaller than their
IRS1KO counterparts, while there were no signiﬁcant
differences in the body weights of the controls or D2KO
animals (Table 1). Thus, the body mass phenotype of the
conventional IRS1KO (20,21) was also maintained in the
compound D2KO/IRS1KO mice.
Insulin resistance in the individual IRS1KO and D2KO/
IRS1KO mice was conﬁrmed by insulin tolerance tests in
25-week-old animals (Fig. 5A). We then evaluated the
ability of the D2KO/IRS1KO animals to secrete insulin in
response to a glucose challenge. Plasma insulin levels
measured before and 30 min after intraperitoneal glu-
cose injection revealed that unlike the hyperinsulinemic
response in the IRS1KO animals, a failure to show
substantive insulin secretory response in injected glu-
cose was observed in the D2KO/IRS1KO animals; the
latter was similar to the hypoinsulinemic response to
glucose challenge observed in the D2KO group (Fig. 5B).
Taken together, these results indicate that D2KO/
IRS1KO animals are as insulin resistant as their IRS1KO
counterparts but fail to show robust compensatory
hyperinsulinemia.
Consistent with previous reports (20), glucose disposal
measured by glucose tolerance tests in IRS1KO animals was
largely similar to that in control animals (Fig. 5C). In con-
trast, D2KO/IRS1KO animals were more severely glucose
intolerant than the D2KO group, with blood glucose levels
400 mg/dl 2 h after glucose challenge (Fig. 5C). To conﬁrm
that these animals have overt diabetes (deﬁned as nonfasting
blood glucose levels 250 mg/dl [27]), we measured the
nonfasting blood glucose levels over a period of 3 days. At
age 25 weeks, D2KO animals exhibited mild hyperglycemia,
whereas IRS1KO and control animals showed euglycemia
and D2KO/IRS1KO animals were severely diabetic with
blood glucose levels approaching 400 mg/dl (Table 1).
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*P < 0.05 and ***P < 0.005 in comparison with controls (A–C)o ra s
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CYCLIN D2 AND COMPENSATORY -CELL HYPERPLASIA
992 DIABETES, VOL. 59, APRIL 2010 diabetes.diabetesjournals.orgDiabetic D2KO/IRS1KO animals have disrupted islet
architecture and severely diminished -cell mass due
to poor proliferation. We next examined islet architec-
ture, -cell mass, and islet density in all groups. Consistent
with previous reports, IRS1KO animals exhibited hyper-
plastic islets (20,35), while D2KO mice showed smaller
islets than controls, although the islet architecture was
normal (13,28). The islets of D2KO/IRS1KO mice were
smaller than D2KO islets, exhibited abnormal architecture,
and had visibly degranulated -cells (Fig. 6A). Quantiﬁca-
tion conﬁrmed a signiﬁcant reduction in -cell mass in the
D2KO/IRS1KO animals (Fig. 6B) that was more severe
than that in their D2KO counterparts. There were no
signiﬁcant changes in 	-cell mass (data not shown). Mea-
surement of the diameter of individual -cells revealed
slightly larger -cells in the D2KO/IRS1KO group, suggest-
ing an attempt at compensation to counter the decreased
-cell mass (Fig. 6C). Taken together, these data suggest
that impaired -cell replication likely accounted for the
decrease in -cell mass in the D2KO/IRS1KO mice.
To assess whether the diminished -cell mass of D2KO/
IRS1KO pancreas was due to an inability of -cells to
replicate as a result of the absence of cyclin D2, we
measured the -cell proliferation index as was done for
the D2KO/LIRKO study. Since -cell replication declines
with age, we chose to examine younger, 6- to 8-week-old
mice (36,37). IRS1KO -cells showed a higher proliferation
index in contrast to a signiﬁcantly lower index in D2KO
and D2KO/IRS1KO -cells, underscoring the importance of
cyclin D2 for -cell replication in this model (Fig. 6D). The
absence of transferase-mediated dUTP nick-end labeling–
positive -cells in 6- to 8-week-old mice in the D2KO/
IRS1KO group suggested that apoptosis is unlikely to
contribute to diminished -cell mass at this age in the
double mutants. However, in 25-week-old mice a higher
rate of apoptosis was detectable in the D2KO and D2KO/
IRS1KO islets, which is consistent with a recent report
(38), although these differences did not reach statistical
signiﬁcance (data not shown). Taken together, our data
indicate that cyclin D2 is required for replication-depen-
dent expansion of -cell mass in response to insulin
resistance.
Upregulation of expression of alternative D-type cy-
clins fails to initiate proliferation in replication-
competent -cells. We next explored whether the
absence of cyclin D2 in D2KO/IRS1KO animals resulted in
an upregulation of other members of the D-type cyclin
family using immunohistochemistry (Fig. 7). In control
and IRS1KO pancreas sections, cyclin D1 was weakly
expressed in both endocrine and exocrine cells (Fig. 7A
and C) and cyclin D3 (Fig. 7I and K) was absent. In the
D2KO pancreas, cyclin D1 was detected in both endocrine
and exocrine cells (Fig. 7B) and cyclin D3 was weakly
expressed in the nuclei of some -cells (Fig. 7J). In
contrast, in the D2KO/IRS1KO pancreas, cyclin D1 expres-
sion was present (Fig. 7D) and cyclin D3 was expressed
strongly in virtually all nuclei compared with a low-
intensity expression in D2KO pancreas (Fig. 7L). The
enhanced expression of cyclin D3 and the presence of
cyclin D1 in D2KO/IRS1KO animals indicated that despite
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were unable to compensate for the absence of cyclin D2,
further reinforcing the conclusion that cyclin D2 is
essential for expansion of -cell mass in response to
insulin resistance.
DISCUSSION
The presence of an adequate functional -cell mass is
critical for maintaining euglycemia in mammals. In states
of altered metabolic demand, e.g., pregnancy or high-fat
feeding, healthy -cells maintain euglycemia, by increasing
insulin secretion, through an elevated -cell mass, or both
(39). Indeed, 20% of obese insulin-resistant individuals
develop type 2 diabetes, and a majority of insulin-resistant
humans are capable of maintaining euglycemia by -cell
compensation (9,40). Recent studies focused on genomic
analyses of type 2 diabetic patients have reported poly-
morphisms in genes that are close to those coding for key
cell-cycle regulators (41,42); these experiments suggest
that expansion of -cell mass are linked to proteins in
cell-cycle progression. In this study, we provide direct
genetic evidence that the cell cycle protein cyclin D2 is
essential for compensatory -cell expansion in response to
insulin resistance.
We have reported earlier that cyclin D2 is essential for
the physiological remodeling of -cell mass in the postna-
tal period (13,28). To address whether cyclin D2 is also
required for -cell expansion in states of insulin resis-
tance, we crossed the cyclin D2 knockouts with two
mouse models that exhibited varying degrees of insulin
resistance. We chose the LIRKO model because it is tissue
speciﬁc and is characterized by severe resistance and a
dramatic -cell hyperplastic response (22). For the second
model, we used mice lacking IRS1, which exhibited mild
insulin resistance but still manifested islet hyperplasia
(20,21). The presence of a signiﬁcantly increased number
of proliferating -cells in the islets from both models
indicates the presence of hyperplasia—in part due to
replication. Whereas imposition of cyclin D2 insufﬁciency
led to diabetes in both models, severe hyperglycemia was
evident in the D2KO/LIRKO compound knockouts at a
much earlier age, suggesting that the severity of insulin
resistance and the availability of cyclin D2 are important
determinants of an appropriate islet hyperplastic re-
sponse. On the other hand, in the IRS1KO mice, which
develop mild-to-moderate postreceptor insulin resistance
(20), the superimposition of cyclin D2 insufﬁciency also
led to the development of diabetes. However, the com-
pound D2KO/IRS1KO mice continued to live until age 25
weeks and more closely mimicked the human progression
of insulin resistance–mediated type 2 diabetes compared
with the D2KO/LIRKO model. Further, the reduced expres-
sion of two key -cell–speciﬁc markers, PDX1 and GLUT2,
suggests that absence of cyclin D2, in the context of
insulin resistance, can directly inﬂuence -cell function
and proliferation.
Upstream signaling pathways (e.g., insulin/IGF-I) are
crucial in the regulation of -cell replication (rev. in 9) and
may be linked with cyclin D2 in modulating -cell mass.
Indeed, we previously reported that increased -cell rep-
lication in LIRKO mice correlates with increased insulin
levels but not with glucose levels (23). Furthermore, in this
same study, we crossed LIRKO mice with -cell–speciﬁc
insulin receptor knockout (IRKO) mice, a model that
exhibits -cell hypoplasia and manifests a phenotype
resembling human type 2 diabetes (25). Consistent with a
role for the insulin receptor in modulating -cell prolifer-
ation, IRKO/LIRKO mice failed to develop islet hyperpla-
sia and died as early as 8 weeks of age (23). Interestingly,
islets and -cells derived from IRKO mice show reduced
cyclin D2 protein expression (C.H. and R.N.K., unpub-
lished data), and it is possible that this absence of the
cell-cycle protein contributes to poor islet growth and
development of age-dependent diabetes in these mutants
(43,44). Recent experiments have also linked the cyclin/
CDK4 complex with Akt in -cell proliferation, indicating
that Akt1 upregulates cyclin D1 and cyclin D2 levels and
CDK4 activity (45).
control D2KO IRS1KO D2KO/IRS1KO
Cyclin D1
Insulin
DAPI
Cyclin D2
Insulin
DAPI
Cyclin D3
Insulin
DAPI
H G F E
L K J I
D C B A
FIG. 7. Alterations in expression of D-type cyclins in D2KO/IRS1KO islets. Coimmunostaining for insulin (green) and cyclin (red) D1, D2, or D3
in pancreas sections from control, D2KO, IRS1KO, and D2KO mice. A representative islet for each group at magniﬁcation 20 is presented; n 
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nodes in the regulation of the G1-to-S transition during
cell-cycle progression. For example, global knockouts of
CDK4 in mice develop -cell hypoplasia and diabetes
(16,17). Previous work by our own group has shown that
mice with a global knockout of p27, a cell-cycle inhibitor,
regenerate -cells more efﬁciently following streptozocin-
induced diabetes (13), while other investigators have
reported that -cell–speciﬁc overexpression of p27 leads
to islet hypoplasia and diabetes (46). Conversely, the
cell-cycle inhibitor p21, which is the main target of the
tumor suppressor p53, has recently been reported to be
unessential for maintaining -cell mass or function in vivo
(47). In a similar manner, -cell–speciﬁc deletion of pRb, a
protein reported to be a central regulator of the cell cycle,
leads to minimal defects in -cell replication, mass, and
function (48). Therefore, speciﬁc cell-cycle regulators play
a critical role in -cell proliferation regardless of the
redundant expression of complementary family members.
Intriguingly, Lavine et al. (49) have reported an inability to
detect cyclin D2 protein in proliferating human islets that
overexpressed prepro-cholecystokinin. Whether human
-cells utilize cyclin D2 for proliferation in a context-
dependent manner or are dependent on another key cyclin
protein requires further investigation.
While prior studies support a role for PDX-1 in -cell
proliferation, it is unclear whether proteins in the
cyclin/CDK pathway are direct targets of this transcrip-
tion factor. On the other hand, in our study the de-
creased -cell mass in the compound knockouts and
reduced expression of PDX-1 suggest that cyclin D2 is
upstream of the pancreas-duodenum homeodomain
transcription factor. It is likely there are intermediates
that link these two important proteins, and additional
studies are warranted to deﬁne their roles in the regu-
lation of -cell proliferation.
It is worth noting that the cyclin D2 mutants were global
knockouts; therefore, it is possible that lack of cyclin D2 in
putative precursors contributing to neogenesis also de-
pends on cyclin D2–mediated cell-cycle reentry to facili-
tate enhanced -cell mass. Nevertheless, our conclusion
that cyclin D2 is necessary for replication-based -cell
expansion in insulin-resistant states is supported by lin-
eage trace studies, which provide ﬁrm evidence that
self-duplication is the primary source of new -cells in
adult rodents (12). Taken together, our studies support the
hypothesis that cyclin D2, or its analog in humans, is a
potential therapeutic target that can be harnessed to
promote -cell expansion in the treatment of type 1
diabetes and to delay the progression or prevent the
development of type 2 diabetes.
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